Cargando…

The effect of computed tomography parameters on sarcopenia and myosteatosis assessment: a scoping review

Computed tomography (CT) is a valuable assessment method for muscle pathologies such as sarcopenia, cachexia, and myosteatosis. However, several key underappreciated scan imaging parameters need consideration for both research and clinical use, specifically CT kilovoltage and the use of contrast mat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lortie, Jevin, Gage, Grace, Rush, Benjamin, Heymsfield, Steven B., Szczykutowicz, Timothy P., Kuchnia, Adam J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745495/ https://www.ncbi.nlm.nih.gov/pubmed/36065509 http://dx.doi.org/10.1002/jcsm.13068

Ejemplares similares

Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound
por: Lortie, Jevin, et al.
Publicado: (2022)

Corrigendum: Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound
por: Lortie, Jevin, et al.
Publicado: (2022)

Diagnosing sarcopenia and myosteatosis based on chest computed tomography images in healthy Chinese adults
por: Tan, Lingling, et al.
Publicado: (2021)

Computed Tomography-Derived Myosteatosis and Metabolic Disorders
por: Miljkovic, Iva, et al.
Publicado: (2021)

High prevalence of sarcopenia and myosteatosis in patients undergoing hemodialysis
por: Fu, Chen, et al.
Publicado: (2023)

Combination of DXA and BIS Predicts Jump Power Better Than Traditional Measures of Sarcopenia
por: Rush, Benjamin, et al.
Publicado: (2021)

Psoriasis Is Associated With Myosteatosis but Not Sarcopenia: A Case-Control Study
por: Chen, Xiaomei, et al.
Publicado: (2021)

Effects of sarcopenia and myosteatosis are alleviated in reduced port surgery for diverticulitis
por: Schaffler-Schaden, Dagmar, et al.
Publicado: (2023)

The impact of sarcopenia and myosteatosis on postoperative outcomes in patients with inflammatory bowel disease
por: O’Brien, Stephen, et al.
Publicado: (2018)

Prognostic Value of Sarcopenia and Myosteatosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Kim, Dong Wook, et al.
Publicado: (2022)

Sarcopenia and myosteatosis are accompanied by distinct biological profiles in patients with pancreatic and periampullary adenocarcinomas
por: Stretch, Cynthia, et al.
Publicado: (2018)

Sarcopenia and Myosteatosis at Presentation Adversely Affect Survival After Esophagectomy for Esophageal Cancer
por: Srpcic, Matevz, et al.
Publicado: (2020)

Sarcopenia and Myosteatosis as Prognostic Markers in Patients with Advanced Cholangiocarcinoma Undergoing Palliative Treatment
por: Jördens, Markus S., et al.
Publicado: (2021)

Sarcopenia and Myosteatosis Assessed by Magnetic Resonance Enterography May Predict Negative Outcomes in Patients with Crohn’s Disease
por: Eren Cankurtaran, Rasim, et al.
Publicado: (2023)

Relationship between sarcopenia/myosteatosis and frailty in hospitalized patients with cirrhosis: a sex-stratified analysis
por: Feng, Hongjuan, et al.
Publicado: (2021)

Defining sarcopenia and myosteatosis: the necessity for consensus on a technical standard and standardized cut‐off values
por: Westenberg, Lisa B., et al.
Publicado: (2022)

Sarcopenia and Myosteatosis Are Associated with Neutrophil to Lymphocyte Ratio but Not Glasgow Prognostic Score in Colorectal Cancer Patients
por: Aro, Raila, et al.
Publicado: (2022)

Sarcopenia and myosteatosis diagnostic tool for gastrointestinal cancer: creatinine to cystatin C ratio as evaluation marker
por: Liu, Hao, et al.
Publicado: (2023)

Are Sarcopenia and Myosteatosis in Elderly Patients with Pelvic Ring Injury Related to Mortality, Physical Functioning and Quality of Life?
por: Banierink, Hester, et al.
Publicado: (2021)

Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment
por: Ahern, Elizabeth, et al.
Publicado: (2023)

Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
por: Kim, Hong-Kyu, et al.
Publicado: (2023)

The Prognostic Value of Sarcopenia and Myosteatosis in Biliary Tract Cancer After Palliative Treatment With Radiation-Emitting Metallic Stent
por: Chen, Qi, et al.
Publicado: (2022)

Contributory roles of sarcopenia and myosteatosis in development of overt hepatic encephalopathy and mortality after transjugular intrahepatic portosystemic shunt
por: Yin, Liang, et al.
Publicado: (2023)

Assessment of Myosteatosis on Computed Tomography by Automatic Generation of a Muscle Quality Map Using a Web-Based Toolkit: Feasibility Study
por: Kim, Dong Wook, et al.
Publicado: (2020)

Myosteatosis rather than sarcopenia associates with non‐alcoholic steatohepatitis in non‐alcoholic fatty liver disease preclinical models
por: Nachit, Maxime, et al.
Publicado: (2020)

Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
por: Cespiati, Annalisa, et al.
Publicado: (2022)

Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography
por: Kim, Hwi Seung, et al.
Publicado: (2023)

The Role of Sarcopenia and Myosteatosis in Short- and Long-Term Outcomes Following Curative-Intent Surgery for Hepatocellular Carcinoma in a European Cohort
por: Meister, Franziska Alexandra, et al.
Publicado: (2022)

Clinical Relevance of Myopenia and Myosteatosis in Colorectal Cancer
por: Okugawa, Yoshinaga, et al.
Publicado: (2022)

Impact of myopenia and myosteatosis on postoperative outcome and recurrence in Crohn’s disease
por: Pozios, Ioannis, et al.
Publicado: (2022)

Body Composition of Patients Undergoing Radical Cystectomy for Bladder Cancer: Sarcopenia, Low Psoas Muscle Index, and Myosteatosis Are Independent Risk Factors for Mortality
por: Engelmann, Simon U., et al.
Publicado: (2023)

The Presence of Myosteatosis Is Associated with Age, Severity of Liver Disease and Poor Outcome and May Represent a Prodromal Phase of Sarcopenia in Patients with Liver Cirrhosis
por: Geladari, Eleni, et al.
Publicado: (2023)

Bioelectrical impedance analysis for diagnosing sarcopenia and cachexia: what are we really estimating?
por: Gonzalez, Maria Cristina, et al.
Publicado: (2017)

Lack of Correlation of WAIS Digit Span with Clox 1 and the Dementia Rating Scale in MCI
por: Lortie, Jevin Jay, et al.
Publicado: (2012)

Myosteatosis is associated with poor physical fitness in patients undergoing hepatopancreatobiliary surgery
por: West, Malcolm A., et al.
Publicado: (2019)

Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis
por: Montano‐Loza, Aldo J., et al.
Publicado: (2015)

Pelvic muscle size and myosteatosis: Relationship with age, gender, and obesity
por: Pacicco, Thomas, et al.
Publicado: (2019)

Myosteatosis and nlr as predictors of poor outcomes in patients with Covid-19
por: Padilha, D.M.D.H., et al.
Publicado: (2021)

Myosteatosis predicting risk of transition to severe COVID-19 infection
por: Yi, Xiaoping, et al.
Publicado: (2022)

Prognostic Impact of Myosteatosis on Mortality in Hospitalized Patients with COVID-19
por: Kang, Min-Kyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2tt1tt2eos1pbhihcqlnhoimn7